Rohinitib is a Specific eIF4A Inhibitor Used for Acute Lymphoblastic Leukemia Research
eIF4A is an enzymatic core of the eIF4F complex and an indispensable effector of the mTORC1 pathway. In the first place, eIF4A is a popular target for cancer treatments. Due to the inhibitory effect to translation initiation, eIF4A represses the oncogenic activation of HSF1. Moreover, HSF1 is a factor...
BC-LI-0186 is a Selective Inhibitor of LeuRS and RagD Interaction
BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). It competitively binds to the RagD interacting site of LRS (Kd=42.1 nM). At the same time, it has effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation, or the...
Verucopeptin, a HIF-1 and v-ATPase ATP6V1G Inhibitor, Exhibits Antitumor Activity Against MDR Cancers
ATP6V1G, a subunit of the vacuolar H+-ATPase (v-ATPase). In this article, we will introduce a potent ATP6V1G inhibitor, Verucopeptin. Firstly, in vitro. Verucopeptin shows excellent antitumor activity against K562R cells, with an IC50 of 388 nM. Although these cells exhibit resistance to some other chemotherapeutic agents, such as Taxol...